Spots Global Cancer Trial Database for Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Official Title:
Study ID: NCT00406900
Interventions
Study Description
Brief Summary: Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients
Detailed Description: Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dept of Ophthalmology, University of Munich, Munich, , Germany
Contact Details
Name: Ulrich C Schaller, MD
Affiliation: University of Munich, Germany
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
